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2Abstract
Prostate Cancer (PC) is a type of cancer that is often diagnosed at very early stages
due to improved detection among man in the Western World. Current imaging
techniques are not optimal to determine extent of minimal early stage PC even though
this is of great clinical importance. Human PC and high-grade PIN have shown high
Gastrin-Releasing Peptide Receptor (GRPR) expression, while normal prostate tissue
and BPH revealed to be predominantly GRPR-negative. Radiolabelled Gastrin-
Releasing Peptide (GRP) or bombesin (BN) analogues targeting the GRPR can be
used as non-invasive tools to diagnose, monitor and potentially treat PC. These BN
analogues have already proven to be able to image PC in both tumour-bearing mice
and clinical patients showing no important side effects.
It’s desirable that new peptides require fast-track standardised comparative
testing in relevant PC models to select the best performing BN analogues for further
evaluation in patients. Although knowledge about GRPR expression and development
of new BN analogues can be extended, it is time to study performance of BN
analogues for peptide-receptor based imaging in patients validating results of PC
imaging using histopathology as a golden standard.
Keywords: bombesin, Gastrin-Releasing Peptide, peptide receptor imaging, prostatic
neoplasms.
3Introduction
The medical specialism of nuclear medicine focuses on the application of
radiolabelled tracers for scintigraphic imaging or radionuclide therapy of disease.
Molecular nuclear medicine holds the unique potential of being able to find, diagnose
and treat disease as well as to monitor treatment response.
The current evolution of knowledge in molecular biology has resulted in new
targets to detect human cancer specifically. New developments in (radio)chemistry
have improved molecular delivery of radionuclides to disease-target sites.
Consequently this has resulted in the generation of novel tracers. Technical
developments in scintigraphic instruments and reconstruction software have improved
imaging modalities allowing small-animal scintigraphic techniques useful for
experimental nuclear research of, especially rodent, disease models. See for review
(1).
In oncology radioactive iodine introduced in the early 1950s and the widely
used 18F-fluoro-2-deoxy-D-glucose (18F-FDG) have been developed as indicators of
cancer cells. A promising opportunity for nuclear applications in oncology lies in the
development of radiolabelled peptides that target receptors for imaging and therapy.
This technique is based on targeting specific receptors that are overexpressed in tumor
compared to normal tissue with highly selective radiolabelled peptides for specific
imaging and monitoring. Linked to appropriate therapeutic radionuclides these
peptides can also be used as radiotherapeutics in peptide receptor radionuclide therapy
(PRRT).
In order to bring peptide-receptor based modalities into the clinic,
radiopharmaceuticals with high affinity and high specificity for preferably cancer-
specific receptors are required allowing visualisation and quantification of
4radioactivity in the tumour in a reproducible and repeatable manner. See for review
(2). Somatostatin is a well-known peptide, of which analogues have been
implemented successfully in the clinics to visualise and treat various neuroendocrine
tumours (3, 4).
This review focuses on the use of the Gastrin-Releasing Peptide Receptor
(GRPR) as a target for imaging and radionuclide therapy of prostate cancer (PC)
using radiolabelled bombesin (BN) analogues. The potential of these peptides for their
use in early diagnosis, monitoring and therapy of PC will be discussed.
Prostate cancer
PC is the most frequently diagnosed cancer among men in the Western world and is
the third most common cause of death (5). Specific antigen (PSA) PSA has been
increasingly used to detect PC (6), although it has limited diagnostic specificity and
prognostic value (7). The impact of PSA-based screening on survival has recently
been reported by the European Randomised Study of screening for PC (ERSPC) study
showing a significant reduction in death from prostate cancer, but at the cost of
overtreatment (8). Due to PSA-based screening, the number of patients that are
detected with early disease is rising. Although, final diagnosis of PC is made by
histopathological confirmation of transrectal ultrasound-guided prostate biopsies,
staging of the disease is essential for the decision for the most accurate treatment. It
discriminates between organ-confined disease, in which local therapy such as surgery
or radiation may still be beneficial, and PC beyond the confines of the gland for which
a systemic approach like hormonal therapy is the first choice of treatment. None of
the currently used imaging modalities are sufficiently reliable to determine the extent
of disease in early detected PC (9). Non-invasive sensitive imaging strategies to
5accurately diagnose, stage and monitor PC are therefore essential. Radiolabelled
peptide-based imaging by scintigraphy may be the alternative application to fill this
gap and improve diagnostic sensitivity for early PC. Also, PRRT may be an
alternative tumour-specific targeting strategy in progressive patients with metastatic,
therapy-resistant PC.
PET metabolic radiotracers such as 18F-FDG, 11C-choline and 11C-acetate have
been intensively studied for imaging PC. 18F-FDG was found to have a low accuracy
in primary staging of PC mainly due to low metabolic glucose activity and urinary
excretion of the metabolic tracer [10]. Choline and acetate PET was reported useful
for staging of LN disease [10, 11].
ProstaScint (111In-capromab pendetide), a monoclonal antibody against
prostate-specific membrane antigen (PSMA) as a target, is the only nuclear imaging
application for PC-specific imaging. It has been approved by the American Food and
Drug Administration and is put to practice for diagnostic imaging and staging of LN
metastasis of PC (12).
An alternative target for PC imaging may be the GRPR using radiolabelled
BN analogues.
BN for peptide-targeted imaging of PC
Gastrin-Releasing Peptide (GRP) is a 27-amino acid neuropeptide that is the
mammalian homologue of the linear tetradecapeptide BN originally isolated from the
skin of the frog; Bombina bombina. GRP binds selectively to the GRPR. It shares
homology with BN at the amidated C terminal sequence in the final 7 amino acids
(Figure 1).
6Using tumour autoradiography it has been reported that in human samples
GRPRs are expressed at high density on the cell membranes of prostatic
intraepithelial neoplasias (PIN), primary PC and invasive prostatic carcinomas,
whereas normal prostate tissue and, in most cases, benign prostate hyperplasia (BPH)
were predominantly GRPR-negative (13). The underlying molecular mechanisms of
aberrant GRPR expression and/or activation in human PC are unknown at present.
GRP interacts with GRPR inducing cell growth in various tumours including PC (14).
The relation between GRPR and PC stage is still uncertain. PC in xenografts derived
from late stage androgen-independent disease showed lower expression of the GRPR
than xenografts established from early androgen-dependent PC (15). Besides in PC
GRPR is also over expressed in several other human tumour types and metastases
including breast-, colon-, lung-, ovary-, renal, CNS and head or neck squamous cancer
(14, 16).
Four subtypes of the cell surface BN receptor are known. Among them three
are mammalian: the NMB receptor (BB1), Gastrin-Releasing Peptide Receptor
(GRPR/BB2) and BN receptor subtype 3 (BRS-3/BB3). A fourth receptor, BB4, is only
found in amphibians (14, 17). The only well characterised receptor to which GRP and
BN bind with high affinity is the GRPR (BB2).
Research on GRPR and BN-analogues
The finding of GRPR overexpression in PC and other cancer types stimulated the
search for BN/GRP peptide analogues that could bind with high potency to the GRPR.
GRP-antagonistic analogues have been developed to realise antiproliferative effects
and indeed this has led to promising growth-inhibitory effects in human GRPR-
positive PC cell lines and human PC3-bearing mice (18). Besides this approach it was
7also proposed that GRP analogues could be used as molecular tracers for imaging and
treatment of PC tumours, when those analogues would be linked to a radioactive
agent (13, 19). This application has been studied in both preclinical and clinical
settings.
Synthetic BN analogues can be categorized into two different types based on
their structures. Type A-analogues are truncated with only a portion, usually BN [7-
14] at the C terminus, of the peptide retained. This C terminal sequence is generally
thought to be essential for receptor recognition, signal transduction, and biologic
function (Figure 1). Type B analogues on the other hand are synthesized in full length.
In these analogues usually one or more amino acid residues are selectively replaced.
A type A-analogue is generally thought to be favourable while it is more
stable than the full-length type B tetradecapeptides for in vivo applications and still
binds to the GRPR adequately (20, 21). For radiolabelling of GRP-analogues
biomolecules are generally designed in a way to keep the labelling site at distance
from the receptor-binding site, but at the same time tag the radiometal into the
molecule in an irreversible way leading to stable radiolabelled derivatives.
Preclinical
The development of new analogues is mostly aimed at improving the sensitivity and
specificity of GRPR targeting. Several new BN-analogues have been developed and
tested for their potential in early diagnosis, monitoring and therapy in vivo. In a
preclinical setting general peptide characteristics such as stability, biodistribution and
toxicity were often tested using the human PC3 cell line and the experimental PC3
bearing xenograft model.
8A potent 99mTc-based BN analogue designed for GRPR based targeting and
tested in the PC3 xenograft model with the highest absolute tumor-uptake in animals
described in literature, is Demobesin-1 (22). Other promising BN-analogues that were
tested in preclinical studies using PC3 bearing mice include the DOTA chelated
compounds AMBA and Pesin, the DTPA chelated compound MP2653 (Compound 3
in Visser et al.) and [DTPA1, Lys3(Pm-DADT), Tyr4]BN (for amino acid sequence of
native BN and BN-analogues see Table 1) (23-26).
Rogers et al. introduced the radiolabelled BN analogue 64Cu-DOTA-Aoc-
BN[7–14] as the first GRPR targeting radiopharmaceutical to use for PC-imaging
with PET (27). The BN-analogue 18F-FB-[Lys3]BN designed for GRPR-targeted PET
has also been tested showing promising results for PC imaging (28).
At the moment a valid comparison of available analogues for PC detection is
difficult as standardisation between the preclinical studies performed is lacking.
Therefore we recently performed a standardised preclinical study comparing four
DOTA-chelated BN agonists and one N4-chelated BN antagonist (manuscript
submitted).
GRPR will internalise into the cell when it is activated by an agonistic ligand
binding the receptor. Internalisation of the receptor-radioligand complex has always
been thought to be a crucial step for optimal imaging and therapy. It would provide
essential accumulation and retention of radioactivity in the cell, thus increasing the
radioactive signal at the target site. Interestingly, high-affinity somatostatin receptor
antagonists that poorly internalise into tumour cells have recently shown an equal or
even higher tumour uptake and a higher retention rate in preclinical studies as
opposed to agonists, which do internalise (29). Cescato et al showed that GRPR
antagonists may be superior targeting agents compared to GRPR agonists as well
9(30). These data suggest a change of paradigm in which the intensified use of
antagonistic in preference to agonistic analogues would be justified.
PC3 and Du145 cell lines are commonly used in GRPR binding studies. Both
cell lines are androgen-independent and show no expression of the androgen receptor
or PSA; characteristics which are essential to PC patients (31). On the other hand,
both cell lines express high levels of GRPR (32). Therefore they remain functional for
use in GRPR based studies. In a panel of 12 established human PC xenograft models
representing the different stages of human PC, Visser et al. showed that high GRP
receptor density was only observed in androgen-dependent PC xenografts. If this
result can be translated to the clinical situation, it might indicate that high GRPR
expression is predominantly present in the early, androgen-dependent, stages of PC
and not in later stages. In addition, in this preclinical study, androgen ablation
strongly reduced GRPR expression in androgen-dependent tumours indicating that
GRPR expression in human PC is androgen-regulated (15). Thus GRPR based
imaging may be especially relevant in early PC and less suited for hormone-treated
patients with late stage disease.
Clinical
Few BN-analogues have been studied in PC patients. Van der Wiele published
clinical data on 99mTc-RP527 in four androgen independent PC patients with
metastatic bone lesions. Selective uptake was observed in one patient and 50% of the
bone lesions could be visualised by SPECT in this patient. No short-term adverse or
subjective effects were described in any of the subjects (33).
The GRP analogue [Leu13]BN which complexes with 99mTc was described in
an article by Varvarigou et al (34). Herein [Leu13]BN showed to be a promising BN-
10
analogue in GRPR expressing malignancies other than PC. A first clinical study using
99mTc-[Leu13]BN for imaging in an androgen-dependent PC patient by De Vincentis
et al. resulted in the visualisation of the primary PC in this patient without observing
relevant side-effects (35). Scopinaro et al. proceeded evaluating the same analogue in
8 PC patients and reported all 8 primary PCs to be visualized in the prostate fossa by
SPECT while 2 patients with benign adenomas did not show uptake. In this study
SPECT showed uptake in obturator nodes which was proven to be cancer-specific
after histopathology in 3 patients. MRI or CT did not show these LN metastases (36).
After this study Vincentis et al. reported SPECT-detected PC in 12/12 patients with
androgen-dependent PC and loco-regional LN visualisation in 4 patients. Eleven
patients got operated and results were histologically confirmed by surgical specimens.
No short-term adverse effects were stated (37). In a phase I study in hormone
refractory PC patients aiming at PC therapy, using the 177Lu-labelled BN analogue
AMBA, SPECT imaging revealed lesions in 5 out of 7 patients with adittional high
pancreatic uptake of radioactivity (38). For an overview of clinical PC-imaging
studies see table 2.
Recently, Froberg et al reported high uptake of the BN-agonist MP2248 and
antagonist Demobesin-1 in the pancreatic region of 4 PC patients. Retention in the
pancreas after injection of 111In-MP2248 was much longer than retention of 99mTc-
Demobesin-1 (39).
Only very few PET studies have been reported to date for visualisation and
quantification of GRPR expression in PC patients. A clinical study using 68Ga-
DOTABOM has been described by Hofmann et al. (40).
Future prospectives
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Although expression of the GRPR in various tissue types and tumours has been
studied it requires further investigation. In case of PC, knowledge about the androgen
regulation of GRPR is of great clinical relevance, as it will strongly determine the
potential use of BN-based imaging and therapy in the different stages of PC.
A valid comparison of BN-analogues for PC detection, based on literature, is
difficult as standardisation between studies is lacking. Differences in potency between
existing and future BN-analogues need to become clear. Standardised studies with
appropriate design to compare analogues are therefore required.
The field of radiolabelled peptides for receptor-based targeting of PC is
evolving. New BN-analogues are being designed in order to improve characteristics
like specificity, sensitivity and stability in vivo. BN-peptides should have high affinity
for to the GRPR, remain intact in vivo for a long time and their clearance from
circulation should be fast. Furthermore, for peptide-receptor targeting, receptors of
interest should ideally be highly expressed in the disease tissue only. High expression
in (non-cancerous) non-targeted tissue will cause non-specific peptide binding
resulting in a high background signal while scanning and toxicity to healthy tissue
when therapy is concerned. When developing a BN-analogue, besides taking its
amino acid sequence into consideration, attention should be paid to the selection of an
appropriate chelator while this determines which radionuclides can be complexed
with the analogue.
Recent findings suggest that antagonistic GRPR-based peptides show higher
tumour uptakes and radioactivity retention in PC tissue compared to agonistic
peptides with comparable binding affinities. This finding paves the way for intensified
development of new BN-antagonists. Also from a pharmacological point of view this
change in paradigm is favourable, as antagonists may not induce the endocrinological
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side effects known from agonists, such as stimulation of tumour growth. Especially
when a therapeutic dose is taken into account, agonistic BN-peptides could cause
(side-)effects for PC patients. More research needs to be done to reveal the underlying
mechanism in binding difference between agonistic and antagonistic peptides. To
improve peptide-receptor targeting and increase the dose in target cells it might be
suggested to test a cocktail of BN-agonists and antagonists for simultaneous
administration.
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Legends
Table 1
Amino acid sequence of native BN (14 amino acids) and the BN-analogues described.
BN = bombesin, Ref(s) = reference(s).
Chelators: N4 = 6-{p-[(carboxymethoxy)acetyl]aminobenzyl}-1,4,8,11-
tetraazaundecane, DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid,
DTPA = Diethylene triamine pentaacetic acid, Pm-DADT = diaminedithiol, FB = 4-
Fluorobenzoyl, N3S = dmgly-L-ser-L-cys(acm).
Linkers: BzDig = p-aminobenzyldiglycolic acid, PEG = polyethylene glycol, Aoc = 8
carbon linker, Gly-5aVa = 5-amino-valeroyl, Aca = 6-amino-n-hexanoic acid.
Introduced amino acids: Phe = Phenylalanine, ACMPip = 4-Amino-
carboxymethylpiperidine (non-natural amino acid), Tha = β-(2-Thienyl)-alanine (non-
natural amino acid), β-Ala = β-Alanine (non-natural amino acid), Nle = Norleucine, 
Lys = Lysine, Cys = Cysteine, Pro = Proline, Tyr = Tyrosine.
Table 2
Overview of clinical studies using BN-analogues for PC-tumour imaging patients
Ref = reference, BN = bombesin, PC = prostate cancer, AI = androgen independent,
AD = androgen dependent, + = visualized by scintigraphy, - = not visualized by
scintigraphy, pt(s) = patient(s), h.c. = histologically confirmed, BC = breast
carcinoma, BAp = benign adenoma of the prostate, LN = lymph node, EPS =
extraprostatic spread.
Figure 1
Amino acid sequence of the 27-amino acid neuropeptide GRP and its mammalian
homologue; the linear tetradecapeptide BN.
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Table 1
Analogue Ref(s) Radionuclide Chelator Linker Amino acid sequence
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Native BN [14] pGlu Gln Arg Leu Gly Asn Gln Trp Ala Val Gly His Leu Met-NH2
Demobesin-1 [22] 99mTc N4 BzDig DPhe Gln Trp Ala Val Gly His
Leu-
NHEt
AMBA [23,38] 177Lu DOTA G-4-aminobenzyl Gln Trp Ala Val Gly His Leu Met-NH2
Pesin [24] 68/67Ga, 177Lu DOTA dPEG4 Gln Trp Ala Val Gly His Leu Met-NH2
MP2653 [25] 111In DTPA ACMPip Tha Gln Trp Ala Val -Ala His Tha Nle-NH2
[DTPA1,Lys3
(Pm-DADT),
Tyr4]BN*
[26] 99mTc Pm-DADT** pGlu Gln Lys Tyr Gly Asn Gln Trp Ala Val Gly His Leu Met-NH2
Aoc-BN(7-14) [27] 64Cu DOTA Aoc Gln Trp Ala Val Gly His Leu Met-NH2
[Lys3]BN [28] 18F FB pGlu Gln Lys Leu Gly Asn Gln Trp Ala Val Gly His Leu Met-NH2
RP527 [33] 99mTc N3S Gly-5aVa Gln Trp Ala Val Gly His Leu Met-NH2
[Leu13] BN [34-37] 99mTc Aca*** Cys Gln Arg Leu Gly Asn Gln Trp Ala Val Gly His Leu Met-NH2
MP2248 [39] 111In DTPA Pro Gln Arg Tyr Gly Asn Gln Trp Ala Val Gly His Leu Met-NH2
DOTABOM [40] 68Ga DOTA
* In this compound DTPA is not used as a chelator for radionuclide complexation, but as a built-in pharmacokinetic modifier to reduce
hepatobiliary clearance.
** Linked to Lys on position 3.
*** In between amino acids 1 and 2.
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Table 2
Authors Ref Radionuclide BN-analogue Total activity
(MBq)
Peptide
mass
PC population
in study
PC
+
Extra
Van der Wiele et al [33] 99mTc
(SPECT)
RP527 555 3 ng/kg 4 AI 1 In the one PC+ pt 50% of h.c. bone
lesions visualized
4/6 BC pts+
De Vincentis et al [35] 99mTc
(SPECT)
[Leu13]BN 185 0,7 µg 1 AD 1
Scopinaro et al [36] 99mTc
(SPECT)
[Leu13]BN 185 0,7 µg 8 AD 8 3LN+ all h.c.; all negative MRI/CT
2 benign PC pts -
De Vincentis et al [37] 99mTc
(SPECT)
[Leu13]BN 185 0,7 µg 12 AD 12 2 BAp pts-
4LN+ all h.c.; 3/4 positive CT/MRI
PC+ h.c. in 11/12 pts
Bodei et al [38] 177Lu
(SPECT)
AMBA 1140-1940 Not
mentioned
7 AI 5 Study primarily aimed for PC
therapy
Hoffman et al [40] 68Ga
(PET)
DOTABOM 26-80 24 nmol 11 AD 11 3 Ln+ & 2 pts with EPS+ (all h.c.)
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Figure 1
Gastrin releasing peptide
Ala-Pro-Val-Ser-Val-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Try-Pro-Arg-
(Gly-Asn-His-)Trp-Ala-Val-Gly-His-Leu-Met-NH2
C terminus
Bombesin
pGlu-Gln-Arg-Leu-
(Gly-Asn-Gln-)Trp-Ala-Val-Gly-His-Leu-Met-NH2
C terminus
